Search Results

RELIEF THERAPEUTICS Holding SA announces the results of its annual general meeting (AGM) of shareholders, which took place in Geneva today.

RELIEF THERAPEUTICS Holding SA announces the results of the extraordinary general meeting of shareholders, which took place in Geneva , Friday, April 26, 2024.

Ferring Pharmaceuticals today launched a new Male Fertility program on Ferring’s Fertility Out Loud platform that empowers men to take the initiative to understand their fertility status.

Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply.

Ferring Pharmaceuticals today announced the presentation of two analyses of data at the American Society of Pain and Neuroscience (ASPN) 2024 Annual Meeting, for SI-6603, an investigational therapy intended to treat radicular leg pain associated with lumbar disc herniation (LDH).

Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of data looking at the efficacy and safety profile of SI-6603 (generic name: condoliase), an investigational product intended to treat radicular leg pain associated with lumbar disc herniation (LDH).

Ferring published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates, but an increase of +1% at constant exchange rates.

ExcellGene SA proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization based in the USA.

Ferring Pharmaceuticals today announced start up of new studies in the United States (U.S.) for three new ADSTILADRIN in BLadder cancEr (ABLE) clinical trials in patients with non-muscle invasive bladder cancer (NMIBC) with plans to expand select clinical trials outside of the U.S. later this year.

Stryker (NYSE: SYK), a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France -based joint replacement company, from Menix.